(redirected from hypogonadotropic hypogonadism)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.
Related to hypogonadotropic hypogonadism: hypergonadotropic hypogonadism, primary hypogonadism


 (hī′pō-gō′năd-ĭz′əm, -gŏn′ə-dĭz′əm)
Inadequate functioning of the testes or ovaries as manifested by deficiencies in gametogenesis or the secretion of gonadal hormones.


(ˌhaɪ pəˈgoʊ næˌdɪz əm, -ˈgɒn æ-)

n. Pathol.
1. diminished hormonal or reproductive functioning in the testes or the ovaries.
2. a manifestation of this, as delayed pubescence.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hypogonadism - incompetence of the gonads (especially in the male with low testosterone); results in deficient development of secondary sex characteristics and (in prepubertal males) a body with long legs and a short trunk
eunuchoidism, male hypogonadism - the state of being a eunuch (either because of lacking testicles or because they failed to develop)
Kallman's syndrome - hypogonadism with anosmia; a congenital sexual disorder that prevents the testicles from maturing at puberty
incompetence - inability of a part or organ to function properly
References in periodicals archive ?
For males, Gonal-f(R) has been approved in 56 countries worldwide for gonadal dysfunction associated with absence of sperm in the semen or male hypogonadotropic hypogonadism.
Background: Idiopathic hypogonadotropic hypogonadism (IHH) has been observed to occur in men with premature ejaculation (PE).
Klinefelter syndrome with hypogonadotropic hypogonadism and absence of Leydig cells [in Spanish].
A clear, colorless gel containing 1% testosterone for replacement therapy in men with primary or hypogonadotropic hypogonadism.
Post study analysis of the population studied in a recently completed Androxal[TM] trial was consistent with men who had Adult-Onset Idiopathic Hypogonadotropic Hypogonadism (AIHH).
Hypogonadotropic hypogonadism manifests during adolescence, a consequence of luteinizing hormone and follicle-stimulating hormone deficiencies secondary to both hypothalamic and pituitary dysfunction (11).
The topics include the secular trend of timing of puberty, the adrenal function of low-birthweight children, the molecular genetics of isolated hypogonadotropic hypogonadism and Kallmann syndrome, gonadotropin-releasing hormone analogue treatment for precocious puberty, polycycstic ovary syndrome in adolescence, and present and future options for preserving fertility in female adolescents with cancer.